Docket #: S19-257
Novel compounds inhibit phospholipid synthesis in cancer
Disease indication
Cancer: Renal cell carcinoma (RCC), hepatocellular carcinoma (HCC)
Drug format: Small molecule compounds, alone or in combination with other chemotherapeutic drugs
Drug class: First-in-class
Target: Enzymes in phospholipid metabolic pathway
Research stage and Preliminary data
The inventors demonstrated that various lipogenesis inhibitors suppress cancer proliferation in RCC and HCC lines.
Continued research: The inventors continue to develop SAR for development candidate.
Background: Previous studies have shown that lipid metabolism is frequently perturbed in cancers. Using desorption electrospray mass spectrometry (DESI-MSI), the inventors showed that phospholipid metabolism is altered.
Mode of action: Inhibiting phospholipid metabolism disrupts cancer metabolism, suppressing cancer proliferation. To date, the inventors have demonstrated results for HCC and RCC.
Advantages
- First-in-class approach with potential for treating a wide range of cancers
- This is a novel target in oncology
Patents
- Published Application: WO2021035031
- Published Application: 20220315528
Similar Technologies
-
Method to direct T-cell fate towards T stem cell memory phenotype S17-182Method to direct T-cell fate towards T stem cell memory phenotype
-
An improved CD206 binder for targeted immune checkpoint blockade and delivery to tumor-associated macrophages S23-438An improved CD206 binder for targeted immune checkpoint blockade and delivery to tumor-associated macrophages
-
Tissue engineered 3D models for cancer metastasis and drug screening S19-375Tissue engineered 3D models for cancer metastasis and drug screening